Nicholas C. Turner, MD, PhD, on INAVO120: Final Overall Survival Analysis
2025 ASCO Annual Meeting
Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital, presents final overall survival data from the INAVO120 trial of inavolisib/placebo plus palbociclib and fulvestrant in patients with PIK3CA-mutated, HR-positive, HER2-negative, endocrine-resistant advanced breast cancer (Abstract 1003).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Here at ASCO, we're presenting the overall survival results of the ANAVO-120 trial. This is a trial for patients with metastatic hormone receptor-positive, HER2-negative breast cancer that has got PIK3CA mutations and specifically for patients that are relapsing on endocrine therapy. We know that this is an aggressive type of breast cancer and we're very much in need of new therapies. And so the ANAVO-120 trial randomized these patients in the first-line setting to the standard of care, which was fulvestrant and palbociclib, or the addition of the PI3 kinase inhibitor inavolisib in the triplet. Inavolisib is a novel PI3 kinase inhibitor. It inhibits PIK3CA alpha, but also it degrades the alpha mutant protein and that probably improves the therapeutic window with inavolisib compared to other PI3 kinase inhibitors. And very importantly, inavolisib is combinable with fulvestrant and palbociclib at the maximum single agent doses. And so what we're doing in that triple combination is we're targeting the estrogen receptor, CDK4/6, and the PI3 kinase inhibitor. And by targeting all of these three key aspects of this type of breast cancer, we're really starting to get really significant efficacy. So in the primary readout of ANAVO-120, we demonstrated that adding in inavolisib substantially improved progression-free survival. And now with longer follow-up, we're also demonstrating that adding in inavolisib improved overall survival with a hazard ratio of 0.67, passing the statistical significance barrier. So that's improving overall survival by 33% on average. A median improvement is 7 months. But we also can look at some other really important endpoints in the study, in particular time to first use of chemotherapy. I mean, this is an endpoint that is very important for people, and the addition of inavolisib delayed the time to chemotherapy on average by almost two years. Now why are we seeing such a big improvement in the study? Partly it's that first-line efficacy substantially improving PFS by over half, as well as a substantial improvement in the response rate. And that of course carries through to delaying time to chemotherapy, but also because we're seeing such a reduction in tumor burden with the triplet that also enabled people in the second line to avoid chemotherapy more often. And it's all translated through to that almost doubling in time to chemotherapy. So this is potentially a really important new treatment option for these patients who've relapsed on endocrine therapy with PIK3CA mutant breast cancer.
The ASCO Post Staff
William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses two abstracts on lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). In Abstract 7037, liso-cel with ibrutinib demonstrated better efficacy and safety compared with liso-cel monotherapy, with statistically significant differences for complete response rate and overall response rate. In Abstract 7039, patients with R/R CLL/SLL who had received two or more prior lines of therapy had improved response, delayed progression, and prolonged survival with liso-cel compared with a real-world cohort treated with standard-of-care therapy.
The ASCO Post Staff
Constantine Si Lun Tam, MD, FRACP, FRCPA, MBBS, of Alfred Hospital and Monash University, reviews results from the 5-year follow-up of arm C of the SEQUOIA trial of treatment-naive patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (Abstract 7011).
The ASCO Post Staff
Elena Elez, MD, PhD, of Vall d’Hebron Institute of Oncology, presents updated overall survival data as well as progression-free survival data from the BREAKWATER trial of the first-line use of encorafenib, cetuximab, and mFOLFOX6 in BRAF V600E–mutant metastatic colorectal cancer (LBA3500).
The ASCO Post Staff
Raffaele Califano, MD, of the Christie NHS Foundation Trust and the University of Manchester, discusses outcomes by osimertinib resistance mechanisms in MARIPOSA-2, a study that evaluated the efficacy of the bispecific antibody amivantamab-vmjw plus chemotherapy vs chemotherapy in patients with EGFR-mutant advanced NSCLC after disease progression on osimertinib (Abstract 8639).
The ASCO Post Staff
Karen Eubanks Jackson, Founder and Chief Executive Officer of Sisters Network Inc. and recipient of the 2025 ASCO Patient Advocate Award, discusses her 30-year-long effort to support patients with breast cancer in the Black community. Sisters Network is focused on raising awareness of early screening for breast cancer, providing financial assistance, and addressing the disparities Black women face in breast cancer care and outcomes.